Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Randall S Stafford , Veronica Monti , Jun Ma Added: 3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin… View more

Prevention & Chronic Conditions

Demographic
Author(s): Randall S Stafford , Veronica Monti , Jun Ma Added: 3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin… View more

Prevention & Chronic Conditions

MI/ACS
HRS 2020: UNTOUCHED Trial Primary Results
Author(s): Michael R Gold Added: 3 years ago
Dr Michael R Gold (Medical University of South Carolina, Charleston, SC, US) discusses the primary results of the UNTOUCHED trial. The UNTOUCHED trial assesed the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death. Questions: 1. What was the rationale behind the UNTOUCHED… View more

Electrophysiology & Arrhythmia
Author(s): Charles H Hennekens , Danielle Hollar Added: 3 years ago
While the proximate cause of virtually all acute cardiovascular disease (CVD) syndromes is thrombosis, the principal underlying cause is atherosclerosis.1 With respect to aspirin, in basic research this drug irrepressibly acetylates the active site of cyclo-oxygenase in platelets which inhibits thromboxane A2, a powerful promoter of aggregation.2 In randomized trials of secondary prevention and… View more

Prevention & Chronic Conditions
Dyslipidemia: Current Therapies and Guidelines for Treatment
Author(s): Edward T Carreras , Donna M Polk Added: 3 years ago
Cardiovascular disease affects more than one-third of American adults and is the leading cause of mortality in the United States and worldwide.1 Only 4.5 % of those over the age of 20 meet the ideal levels of the seven metrics of cardiovascular health including cholesterol levels.1 Of modifiable risk factors, including smoking, hypertension, diabetes, and obesity, dyslipidemia has been shown to… View more

Prevention & Chronic Conditions
Author(s): Darwin Jeyaraj , David S Rosenbaum Added: 3 years ago
Heart disease is the leading cause of death in the US with 700,000 deaths annually, of which 460,000 are attributable to sudden cardiac death (SCD). SCD is usually attributed to ventricular fibrillation (VF). Despite recent reductions in cardiac mortality from other causes, the incidence of SCD remains high with minimal decline in the last decade. The large majority of patients who suffer life… View more

Electrophysiology & Arrhythmia
Aspirin and Statins to Decrease Risks of Cardiovascular Disease - The Need for Wider Utilization
Author(s): Charles H Hennekens , Danielle Hollar , Arthur S Agatston Added: 3 years ago
While the proximate cause of virtually all acute cardiovascular disease (CVD) syndromes is thrombosis, the principal underlying cause is atherosclerosis. With respect to aspirin, in basic research this drug irrepressibly acetylates the active site of cyclo-oxygenase in platelets which inhibits thromboxane A2, a powerful promoter of aggregation. In randomized trials of secondary prevention and… View more

Prevention & Chronic Conditions
Author(s): Leslee J Shaw , C Noel Bairey Merz , Steven E Reis , et al Added: 3 years ago
Recent findings from landmark clinical trials, such as the Women's Health Initiative (WHI)1,2, have significantly altered current thinking about the role of postmenopausal hormone therapy (HT) in cardiovascular disease (CVD) prevention. HT was a therapy widely accepted by women and physicians, often used for CVD prevention purposes, based on observational epidemiologic data and plausible… View more

Prevention & Chronic Conditions

Demographic
Foreword

Article

Author(s): Gregory J Dehmer Added: 3 years ago
Before 1900, infectious diseases and malnutrition were the most common causes of death. However, as robust economies developed, the common causes of death in these economies shifted to cardiovascular diseases and cancer. This shift was largely due to improved nutrition and public health measures. At the same time, easier access to less expensive foods with a higher fat content has led to an… View more

Heart Failure
ACC 23: Lipid Management & the CLEAR Trial with Dr Michos
Author(s): Erin D Michos Added: 1 year ago
ACC.23/WCC — Dr Erin D Michos, preventive cardiologist, (Johns Hopkins University School of Medicine, US) joined us in New Orleans to comment on the new data from the CLEAR-Outcomes trial, that looked at the impact of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or those at high risk of developing it who are statin intolerant… View more

Prevention & Chronic Conditions